BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

...including Xencor Inc. (NASDAQ:XNCR); Nanobiotix S.A. (Euronext:NANO); EpiVax Inc. (Providence, R.I.); Jeffrey Bacha, co-founder of DelMar Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Clinical News

DelMar reports Phase II data for VAL-083 in recurrent GBM

...is known as DAG for Injection, to treat chronic myelogenous leukemia (CML) and lung cancer. DelMar Pharmaceuticals Inc....
...of life (QOL) and pharmacokinetics Status: Phase II data Milestone: NA Sandi Wong DAG for Injection, dianhydrogalactitol (VAL-083) DelMar Pharmaceuticals Inc....
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...Strategy Officer Stephen Von Rump as CEO and Director Austin Lewis as chairman. Cancer company DelMar Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Financial News

DelMar raises $10M in registered direct offering

...Cancer company DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) said on Sept. 22 it closed a registered direct offering, raising $10...
...8 million shares at $1.25. H.C. Wainwright acted as placement agent. DelMar Pharmaceuticals Inc. (NASDAQ:DMPI), Vancouver, B.C. Jennie Walters DelMar Pharmaceuticals Inc....
BioCentury | Sep 15, 2017
Clinical News

DelMar starts Phase II of VAL-083 for MGMT-unmethylated GBM

...the trial is funded under a collaboration with Guangxi Wuzhou Zhongheng Group Co. Ltd. (Shanghai:600252). DelMar Pharmaceuticals Inc....
...Milestone: Additional Phase II data (mid-2018); additional Phase II data (year end 2018) Jennie Walters DAG for Injection VAL-083 DelMar Pharmaceuticals Inc. Guangxi...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:BOLD) 4/18/17 $86.3 $403.7 $530.4 31% Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) 4/18/17 $388.1 $4,551.2 $3,881.2 -15% DelMar Pharmaceuticals Inc....
BioCentury | Apr 14, 2017
Financial News

DelMar Pharmaceuticals completes direct public offering

...On April 13, cancer company DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) raised $9 million through the sale of 2.8 million...
...five-year warrants to purchase up to 2.1 million shares at $3.50. DelMar Pharmaceuticals Inc. (NASDAQ:DMPI), Vancouver, B.C. Alicia Parker DelMar Pharmaceuticals Inc....
BioCentury | Jan 27, 2017
Clinical News

VAL-083: Ph II started

...is known as DAG for Injection, to treat chronic myelogenous leukemia (CML) and lung cancer. DelMar Pharmaceuticals Inc....
...safety, quality of life (QOL) and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu DAG for Injection VAL-083 DelMar Pharmaceuticals Inc. dianhydrogalactitol DNA...
BioCentury | Sep 19, 2016
Company News

Accurexa, DelMar Pharma deal

...and lung cancer. The companies did not respond to inquiries. Accurexa Inc. (OTCQX:ACXA), Newark, Del. DelMar Pharmaceuticals Inc....
BioCentury | May 9, 2016
Financial News

DelMar Pharma completes private placement of convertible preferred stock

DelMar Pharmaceuticals Inc. (OTCQX:DMPI), Vancouver, B.C. Business: Cancer Date completed: 2016-05-05 Type: Private placement of convertible preferred stock Raised: $5.6 million Shares: 700,238 Price: $8 Shares outstanding prior: 40.3 million Investors: Accredited investors; company management;...
Items per page:
1 - 10 of 37
BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

...including Xencor Inc. (NASDAQ:XNCR); Nanobiotix S.A. (Euronext:NANO); EpiVax Inc. (Providence, R.I.); Jeffrey Bacha, co-founder of DelMar Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Clinical News

DelMar reports Phase II data for VAL-083 in recurrent GBM

...is known as DAG for Injection, to treat chronic myelogenous leukemia (CML) and lung cancer. DelMar Pharmaceuticals Inc....
...of life (QOL) and pharmacokinetics Status: Phase II data Milestone: NA Sandi Wong DAG for Injection, dianhydrogalactitol (VAL-083) DelMar Pharmaceuticals Inc....
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...Strategy Officer Stephen Von Rump as CEO and Director Austin Lewis as chairman. Cancer company DelMar Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Financial News

DelMar raises $10M in registered direct offering

...Cancer company DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) said on Sept. 22 it closed a registered direct offering, raising $10...
...8 million shares at $1.25. H.C. Wainwright acted as placement agent. DelMar Pharmaceuticals Inc. (NASDAQ:DMPI), Vancouver, B.C. Jennie Walters DelMar Pharmaceuticals Inc....
BioCentury | Sep 15, 2017
Clinical News

DelMar starts Phase II of VAL-083 for MGMT-unmethylated GBM

...the trial is funded under a collaboration with Guangxi Wuzhou Zhongheng Group Co. Ltd. (Shanghai:600252). DelMar Pharmaceuticals Inc....
...Milestone: Additional Phase II data (mid-2018); additional Phase II data (year end 2018) Jennie Walters DAG for Injection VAL-083 DelMar Pharmaceuticals Inc. Guangxi...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:BOLD) 4/18/17 $86.3 $403.7 $530.4 31% Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) 4/18/17 $388.1 $4,551.2 $3,881.2 -15% DelMar Pharmaceuticals Inc....
BioCentury | Apr 14, 2017
Financial News

DelMar Pharmaceuticals completes direct public offering

...On April 13, cancer company DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) raised $9 million through the sale of 2.8 million...
...five-year warrants to purchase up to 2.1 million shares at $3.50. DelMar Pharmaceuticals Inc. (NASDAQ:DMPI), Vancouver, B.C. Alicia Parker DelMar Pharmaceuticals Inc....
BioCentury | Jan 27, 2017
Clinical News

VAL-083: Ph II started

...is known as DAG for Injection, to treat chronic myelogenous leukemia (CML) and lung cancer. DelMar Pharmaceuticals Inc....
...safety, quality of life (QOL) and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu DAG for Injection VAL-083 DelMar Pharmaceuticals Inc. dianhydrogalactitol DNA...
BioCentury | Sep 19, 2016
Company News

Accurexa, DelMar Pharma deal

...and lung cancer. The companies did not respond to inquiries. Accurexa Inc. (OTCQX:ACXA), Newark, Del. DelMar Pharmaceuticals Inc....
BioCentury | May 9, 2016
Financial News

DelMar Pharma completes private placement of convertible preferred stock

DelMar Pharmaceuticals Inc. (OTCQX:DMPI), Vancouver, B.C. Business: Cancer Date completed: 2016-05-05 Type: Private placement of convertible preferred stock Raised: $5.6 million Shares: 700,238 Price: $8 Shares outstanding prior: 40.3 million Investors: Accredited investors; company management;...
Items per page:
1 - 10 of 37